×

Do you want to link to this External Website and leave Amgen.nl?

YOU ARE NOW LEAVING THIS WEBSITE. Amgen Netherlands takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Wilt u deze Externe Website bezoeken en Amgen.nl verlaten?

U verlaat nu de website van Amgen Nederland. Amgen Nederland draagt geen verantwoordelijkheid voor, en oefent geen controle uit, over de organisaties, meningen or juistheid van de informatie van deze server of website.

Hematology (blood)



Aranesp is a medicine to treat anemia. Anemia is when your blood does not contain enough red blood cells and the symptoms may be fatigue, weakness and shortness of breath. Aranesp is used to treat symptomatic anemia that is associated with chronic renal failure (kidney failure) in adults and children. Aranesp is also used to treat symptomatic anemia in adult cancer patients with non-myeloid malignancies who are receiving chemotherapy.

Aranesp is a medicine which contains the active substance darbepoetin alfa, a product to treat anemia. Anemia is when your blood does not contain enough red blood cells and the symptoms may be fatigue, weakness and shortness of breath.

Aranesp works in exactly the same way as the natural hormone erythropoietin.Erythropoietin is produced in your kidneys and encourages your bone marrow to produce more red blood cells. The active substance of Aranesp is darbepoetin alfa produced by gene-technology in Chinese Hamster Ovary Cells (CHO-K1).

If you have chronic renal failure

Aranesp is used to treat symptomatic anemia that is associated with chronic renal failure (kidney failure) in adults and children. In kidney failure, the kidney does not produce enough of the natural hormone erythropoietin which can often cause anemia.

Because it will take your body some time to make more red blood cells, it will be about four weeks before you notice any effect.Your normal dialysis routine will not affect the ability of Aranesp to treat your anemia.

If you are receiving chemotherapy

Aranesp is used to treat symptomatic anemia in adult cancer patients with non-bone marrow cancers (non-myeloid malignancies) who are receiving chemotherapy. One of the main side effects of chemotherapy is that it stops the bone marrow producing enough blood cells.

Towards the end of your chemotherapy course, particularly if you have had a lot of chemotherapy, your red blood cell count may fall making you anemic.

BLINCYTO is used to treat adults with acute lymphoblastic leukaemia. BLINCYTO is used when acute lymphoblastic leukaemia has come back or has not responded to previous treatment (referred to as relapsed/refractory acute lymphoblastic leukaemia).

BLINCYTO is used to treat children (≥ 1 year old), teenagers and young adults with acute lymphoblastic leukaemia when previous treatments have not worked or have stopped working.

It is also used in patients with acute lymphoblastic leukaemia who still have a small number of cancer cells remaining after previous treatment (referred to as minimal residual disease).

Acute lymphoblastic leukaemia is a cancer of the blood in which a particular kind of white blood cell called “B-lymphocyte” is growing out of control. This medicine works by enabling your immune system to attack and destroy these abnormal white blood cancer cells.

The active ingredient in BLINCYTO is blinatumomab.

This belongs to a group of medicines called antineoplastic agents which target cancer cells.

Kyprolis is used to treat adult patients with multiple myeloma who have had at least one previous treatment for this disease. Multiple myeloma is a cancer of plasma cells (a type of white blood cell).

Kyprolis is a medicine that contains the active substance carfilzomib.

Carfilzomib works by blocking the proteasome. The proteasome is a system within the cells that breaks down proteins when they are damaged or no longer needed.By preventing the breakdown of proteins in cancer cells, which are more likely to contain more abnormal proteins, Kyprolis causes the death of cancer cells.

Kyprolis is used to treat adult patients with multiple myeloma who have had at least one previous treatment for this disease.

Multiple myeloma is a cancer of plasma cells (a type of white blood cell).

Kyprolis will be given to you together with lenalidomide and dexamethasone, or only with dexamethasone. Lenalidomide and dexamethasone are other medicines used to treat multiple myeloma.

Nplate is used to treat low platelet (thrombocyte) counts in patients with Immune Mediated Trombocytopenia (also known as ITP).

ITP is a disease in which your body’s immune system destroys its own platelets.

Nplate’s active ingredient is romiplostim, which is a protein used to treat low platelet (thrombocyte) counts in patients with Immune Mediated Trombocytopenia - (also known as ITP).

ITP is a disease in which your body’s immune system destroys its own platelets. Platelets are the cells in your blood that help seal cuts and form blood clots. Very low platelet counts can cause bruising and serious bleeding.Nplate is used to treat patients aged 1 year and over who may or may not have had their spleen removed for chronic ITP and who have been previously treated with corticosteroids or immunoglobulins, where these treatments don’t work.

Nplate works by stimulating the bone marrow (part of the bone which makes blood cells) to produce more platelets.This should help to prevent bruising and bleeding associated with ITP.Nplate’s active ingredient is romiplostim, which is a protein used to treat low platelet counts


Source: Patient information leaflets, Amgen. See www.ema.europa.eu for the most up-to-date versions.